Analysis of the Effect of Polymyxin E Combined with Amikacin in the Treatment of Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacterial Infection
Objective To study the effect of polymyxin E combined with amikacin in the treatment of pneumonia caused by multidrug-resistant gram-negative bacterial infection.Methods Patients with pneumonia caused by multidrug-resistant gram-negative bacterial infection admitted to the General Hospital of Jinshui District Zhengzhou City from December 2020 to December 2022 were selected.Among them,49 patients treated with polymyxin E + amikacin were set as the research group,and those treated with amikacin were set as the reference group according to the 1:1 pairing principle,with a total of 98 cases in both groups.The treatment effectiveness,forced vital capacity(FVC),the ratio of the volume of air that can be forcibly exhaled in the first second to the forced vital capacity(FEV1/FVC),peak expiratory flow rate(PEF),maximum exhaled volume in the first meter(FEV1),clinical symptom improvement time,procalcitonin(PCT),C-reactive protein(CRP),white blood cell count(WBC),and adverse reaction rate were compared between the two groups.Results The treatment effectiveness rate(83.67%)of the research group was higher than that of the reference group(65.31%),and the difference was statistically significant(P＜0.05);the recovery time of body temperature,lung rales,cough,and sputum symptoms in the research group was shorter than that in the reference group,and the differences were statistically significant(P＜0.05);after treatment,the levels of FVC,FEV1,PEF,and FEV1/FVC in the research group were(3.12±0.44)L,(2.41±0.31)L,(5.63±0.42)L/s,and(77.24±3.85),respectively,which were higher than those in the reference group(2.87±0.35)L,(2.02±0.36)L,(4.28±0.51)L/s,and(70.38±4.06),and the differences were statistically significant(P＜0.05);after treatment,the levels of serum CRP,WBC,and PCT in the research group[(7.43±1.98)mg/L,(7.62±1.38)×109/L,(2.63±0.45)ng/mL]were lower than those in the reference group[(12.55±3.49)mg/L,(10.17±2.03)×109/L,(5.15±0.64)ng/mL],and the differences were statistically significant(P＜0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The treatment of pneumonia caused by multidrug-resistant gram-negative bacterial infection with polymyxin E combined with amikacin is significantly effective,can improve lung function,reduce the level of inflammatory factors,promote the relief of clinical symptoms,and has high safety.
万方数据
维普
